Analyzing bioAffinity Technologies (NASDAQ:BIAF) and Data Knights Acquisition (NASDAQ:DKDCA)

bioAffinity Technologies (NASDAQ:BIAF) and Data Knights Acquisition (NASDAQ:DKDCA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares bioAffinity Technologies and Data Knights Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
Data Knights Acquisition	N/A	N/A	-5.55%

Valuation & Earnings

This table compares bioAffinity Technologies and Data Knights Acquisition’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	11.78	-$7.94 million	($0.90)	-2.88
Data Knights Acquisition	N/A	N/A	$340,000.00	($0.19)	-3.16

Data Knights Acquisition has lower revenue, but higher earnings than bioAffinity Technologies. Data Knights Acquisition is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 35.3% of Data Knights Acquisition shares are held by institutional investors. 44.3% of bioAffinity Technologies shares are held by insiders. Comparatively, 45.7% of Data Knights Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for bioAffinity Technologies and Data Knights Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
Data Knights Acquisition	0	0	0	0	N/A

Volatility & Risk

bioAffinity Technologies has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500. Comparatively, Data Knights Acquisition has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500.

Summary

Data Knights Acquisition beats bioAffinity Technologies on 7 of the 10 factors compared between the two stocks.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

About Data Knights Acquisition

Data Knights Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. Data Knights Acquisition Corp. was incorporated in 2021 and is based in Frome, the United Kingdom.